Mepolizumab treatment for asthma

Bibliography

• Busse WW, Lemanske RF Jr. Asthma. N Engl J Med 2001;344:350-62
   PubMed Web of Science ®Google Scholar
• Jarvis D, Newson R, Lotvall J, Asthma in adults and its association with chronic rhinosinusitis: the GA2LEN survey in Europe. Allergy 2012;67:91-8
   PubMed Web of Science ®Google Scholar
• Gupta R, Sheikh A, Strachan DP, Anderson HR. Burden of allergic disease in the UK: secondary analyses of national databases. Clin Exp Allergy 2004;34:520-6
   PubMed Web of Science ®Google Scholar
• Turner S, Paton J, Higgins B, Douglas G. British Guidelines on the Management of Asthma Thorax. 2011;66:1104-5
   Google Scholar
• Haldar P, Pavord ID, Shaw DE, Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008;178:218-24
   PubMed Web of Science ®Google Scholar
• Moore WC, Meyers DA, Wenzel SE, National Heart, Lung, and Blood Institute's Severe Asthma Research Program. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010;181:315-23
   PubMed Web of Science ®Google Scholar
• Fitzpatrick AM, Teague WG, Meyers DA, Peters SP, National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program. Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program. J Allergy Clin Immunol 2011;127:382-9
   PubMed Web of Science ®Google Scholar
• Robinson DS. The role of the T cell in asthma. J Allergy Clin Immunol 2010;126:1081-91
   PubMed Web of Science ®Google Scholar
• Woodruff PG, Modrek B, Choy DF, T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009;180:388-95
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Robinson DS. Eosinophils, eosinophilic cytokines (interleukin-5), and antieosinophilic therapy in asthma. Curr Opin Pulm Med 2002;8:33-8
   PubMed Web of Science ®Google Scholar
• Robinson D, Hamid Q, Ying S, Prednisolone treatment in asthma is associated with modulation of bronchoalveolar lavage cell interleukin-4, interleukin-5, and interferon-gamma cytokine gene expression. Am Rev Respir Dis 1993;148:401-6
   PubMed Web of Science ®Google Scholar
• Green RH, Brightling CE, McKenna S, Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002;360:1715-21
   PubMed Web of Science ®Google Scholar
• Tan R, Corren J. Omalizumab in the treatment of asthma. Expert Rev Respir Med 2011;5:747-56
   PubMed Web of Science ®Google Scholar
• Berry MA, Hargadon B, Shelley M, Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 2006;354:697-708
   PubMed Web of Science ®Google Scholar
• Wenzel SE, Barnes PJ, Bleecker ER, A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 2009;179:549-58
   PubMed Web of Science ®Google Scholar
• Corren J, Lemanske RF, Hanania NA, Lebrikizumab treatment in adults with asthma. N Engl J Med 2011;365:1088-98
   PubMed Web of Science ®Google Scholar
• Kips JC, O'Connor BJ, Langley SJ, Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 2003;167:1655-9
   PubMed Web of Science ®Google Scholar
• Castro M, Mathur S, Hargreave F, Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2011;184:1125-32
   PubMed Web of Science ®Google Scholar
• Kolbeck R, Kozhich A, Koike M, MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol 2010;125:1344-53
   PubMed Web of Science ®Google Scholar
• Smith DA, Minthorn EA, Beerahee M. Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody. Clin Pharmacokinet 2011;50:215-27
   PubMed Web of Science ®Google Scholar
• Leckie MJ, ten Brinke A, Khan J, Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000;356:2144-8
   PubMed Web of Science ®Google Scholar
• Buttner C, Lun A, Splettstoesser T, Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions. Eur Respir J 2003;21:799-803
   PubMed Web of Science ®Google Scholar
• Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003;167:199-204
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Flood-Page P, Sehmi R, Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J Allergy Clin Immunol 2003;111:714-19
   PubMed Web of Science ®Google Scholar
• Flood-Page P, Menzies-Gow A, Phipps S, Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003;112:1029-36
   PubMed Web of Science ®Google Scholar
• Flood-Page P, Swenson C, Faiferman I, A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007;176:1062-71
   PubMed Web of Science ®Google Scholar
• Haldar P, Brightling CE, Hargadon B, Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360:973-84
   PubMed Web of Science ®Google Scholar
• Nair P, Pizzichini MM, Kjarsgaard M, Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009;360:985-93
   PubMed Web of Science ®Google Scholar
• Busse WW, Katial R, Gossage D, Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody. in a phase I study of subjects with mild asthma J Allergy Clin Immunol 2010;125:1237-44
   Web of Science ®Google Scholar
• Gevaert P, Van Bruaene N, Cattaert T, Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol 2011;128:989-95
   PubMed Web of Science ®Google Scholar
• Oldhoff JM, Darsow U, Werfel T, Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy 2005;60:693-6
   PubMed Web of Science ®Google Scholar
• Stein ML, Collins MH, Villanueva JM, Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol 2006;118:1312-19
   PubMed Web of Science ®Google Scholar
• Kim S, Marigowda G, Oren E, Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol 2010;125:1336-43
   PubMed Web of Science ®Google Scholar
• Rothenberg ME, Klion AD, Roufosse FE, Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 2008;358:1215-28
   PubMed Web of Science ®Google Scholar
• Busse WW, Ring J, Huss-Marp J, Kahn JE. A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma. J Allergy Clin Immunol 2010;125:803-13
   PubMed Web of Science ®Google Scholar
• Wenzel SE. Eosinophils in asthma–closing the loop or opening the door? N Engl J Med 2009;360:1026-8
   PubMed Web of Science ®Google Scholar
• Pavord ID, Haldar P, Bradding P, Wardlaw AJ. Mepolizumab in refractory eosinophilic asthma. Thorax 2010;65:370
   PubMed Web of Science ®Google Scholar
• Miranda C, Busacker A, Balzar S, Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol 2004;113:101-8
   PubMed Web of Science ®Google Scholar
• Heaney LG, Robinson DS. Severe asthma treatment: need for characterising patients. Lancet 2005;365:974-6
   PubMed Web of Science ®Google Scholar
• Available from: www.dh.gov.uk/en/PublicationsandStatistics/Publications/PublicationsPolicyandGudance/DH_098945
   Google Scholar